Preservation of fresh BCG scarification vaccine at 4, −25, and −70° C M. GheorghiuL. Chambon Original Articles Pages: 11 - 16
Comparison of various BCG preparations in the EORTC — ICIG experimental screening for systemic immunity adjuvants applicable to cancer immunotherapy O. Halle-PannenkoCh. BourutM. Kamel Original Articles Pages: 17 - 23
Antitumor activity and other biological properties of two phenotypes isolated from BCG R. TurcotteM. Quevillon Original Articles Pages: 25 - 30
Studies on the mechanisms of action of BCG I. FlorentinR. HuchetG. Mathé Original Articles Pages: 31 - 39
Enhancement of T suppressor activity in mice by high doses of BCG M. GeffardS. Orbach-Arbouys Original Articles Pages: 41 - 43
The immunoproliferative response of mice to intravenously or subcutaneously injected BCG H. RappaportA. Khalil Original Articles Pages: 45 - 49
Toxicity studies of intravenously administered BCG in baboons S. Jurczyk-ProcykM. MartinH. Rappaport Original Articles Pages: 55 - 61
Toxic effects of massive doses of BCG in mice, guinea pigs, and monkeys V. PortelanceM. QuevillonY. Page Original Articles Pages: 63 - 67
Human toxicology of BCG applied in cancer immunotherapy L. SchwarzenbergM. C. SimmlerJ. L. Pico Original Articles Pages: 69 - 76
1975 current results of the first 100 cytologically typed acute lymphoid leukemia submitted to BCG active immunotherapy G. MatheF. de VassalC. Jasmin Original Articles Pages: 77 - 86
Various uses of BCG and allogeneic acute leukemia cells to treat patients with acute myelogenous leukemia J. A. RussellB. ChapuisR. L. Powles Original Articles Pages: 87 - 91
Present status of BCG immunotherapy of malignant melanoma D. L. MortonF. R. EilberK. P. Ramming Original Articles Pages: 93 - 98
Immunotherapy of breast cancer, malignant melanoma, and acute leukemia with BCG: Prolongation of disease free interval and survival J. U. GuttermanG. M. MavligitE. M. Hersh Original Articles Pages: 99 - 107
BCG in the immunotherapy of Hodgkin's disease and non-Hodgkin's lymphomas B. HœrniJ. ChauvergneC. Lagarde Short Communication Pages: 109 - 112
Increase of null cells in patients submitted to long-term active immunotherapy D. BelpommeR. JosephN. Lelarge Letter To CII Pages: 113 - 114